Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Miscellaneous, Pediatric Leukemia, Pediatrics
N/A
Children
Correlative
Not Available
Friedman, Debra
National
Vanderbilt University
04-20-2005
Key Adverse Events after Childhood Cancer
Other
COGALTE03N1
NCT00082745

Eligibility

0 Years
BOTH
NO
Inclusion Criteria:

ELIGIBILITY CRITERIA - CASES

Diagnosis of primary cancer at age 21 or younger, irrespective of current age

No prior history of allogeneic (non-autologous) hematopoietic cell transplant

Development of one of the following key adverse events at any time following initiation of cancer therapy: * Cardiac dysfunction; please note: case enrollment has been closed due to achievement of target accrual * Ischemic stroke (IS) * Subsequent malignant neoplasm (SMN) * Avascular necrosis (AVN); please note: case enrollment has been closed due to achievement of target accrual

Submission of a blood specimen (or in certain cases a buccal cell specimen) to the Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital as per the requirements; please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's white blood cell (WBC) is > 2,000

Written informed consent from the patient and/or the patient’s legally authorized guardian

In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required

ELIGIBILITY CRITERIA - CONTROLS

CONTROL: Diagnosis of primary cancer at age 21 or younger, irrespective of current age

CONTROLS: No prior history of allogeneic (non-autologous) hematopoietic cell transplant

CONTROLS: No clinical evidence of any of the following key adverse events: * Cardiac dysfunction (CD); please note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's WBC is > 2,000 * Myocardial infarction (MI) * Ischemic stroke (IS) * Avascular necrosis (AVN) * Subsequent malignant neoplasm (SMN)

CONTROLS: Submission of a blood specimen (or in certain cases a buccal cell specimen) to the Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital as per the requirements

CONTROLS: Written informed consent from the patient and/or the patient’s legally authorized guardian

CONTROLS: In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; please note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: